Has Geeta Kurra, MD received payments from drug or device companies?

Yes. Drug and device makers reported $76,411 in general payments to Geeta Kurra, MD across 956 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Geeta Kurra, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Geeta Kurra, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Geeta Kurra, MD

Hematology & Oncology · Merrillville, INNPI 1518035369

Payments from drug & device makers

$76,411in general payments, 2019–2025

Across 956 payments — averaging $79.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Daiichi Sankyo Inc.$23K
AstraZeneca$8K
Jazz Pharmaceuticals Inc.$7K
Avyxa Pharma, LLC$4K
Geron Corporation$3K
Johnson & Johnson$3K
plus $27K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Daiichi Sankyo Inc.	49	$22,793
AstraZeneca(2 entities)	83	$8,196
Jazz Pharmaceuticals Inc.	14	$7,251
Avyxa Pharma, LLC	7	$3,879
Geron Corporation	8	$3,147
Johnson & Johnson(2 entities)	50	$2,994
Onmark, Inc.	10	$2,671
AbbVie	25	$2,539
Takeda Pharmaceuticals U.S.A., Inc.	8	$2,265
Pfizer	52	$2,111
Seagen Inc.	13	$1,577
Springworks Therapeutics, Inc.	4	$1,562
E.r. Squibb & Sons, L.L.C.	64	$1,300
Novartis	61	$1,204
Genentech USA, Inc.	56	$1,172
Merck	57	$1,134
Gilead(2 entities)	24	$1,112
Beigene USA, Inc.	7	$813
Amgen	23	$504
Eisai Inc.	23	$489
Bristol Myers Squibb	27	$481
Sanofi	23	$480
Astellas Pharma US Inc	22	$448
Incyte Corporation	23	$443
Cardinal Health 110 LLC	2	$400
GSK	16	$349
Ipsen Biopharmaceuticals, Inc	7	$310
Lilly USA, LLC	13	$269
Sobi, Inc	4	$255
Exelixis Inc.	12	$250
Puma Biotechnology, Inc.	9	$249
Rigel Pharmaceuticals, Inc.	9	$238
Array Biopharma Inc	8	$200
Bayer	11	$193
Adaptive Biotechnologies Corporation	7	$185
Boehringer Ingelheim	5	$153
Regeneron Healthcare Solutions, Inc.	6	$150
Sumitomo Pharma America, Inc.	6	$145
Deciphera Pharmaceuticals Inc.	5	$131
Pharmaessentia USA Corporation	6	$124
Tempus AI, Inc	2	$122
Acrotech Biopharma Inc.	6	$110
AVEO Pharmaceuticals, Inc.	5	$106
ADC Therapeutics America, Inc.	5	$96
EKOS Corporation	1	$93
Pharmacosmos Therapeutics Inc.	4	$93
Caris MPI, Inc.	3	$91
Sirtex Medical Inc	1	$86
Beone Medicines USA, Inc.	3	$84
Pharmacyclics LLC, An Abbvie Company	4	$84
Tactile Systems Technology Inc	3	$80
EMD Serono, Inc.	4	$72
Blueprint Medicines Corporation	3	$70
Syndax Pharmaceuticals, Inc.	2	$64
Stemline Therapeutics Inc.	2	$57
Tesaro, Inc.	2	$54
Epizyme, Inc.	3	$54
Morphosys, US Inc.	3	$51
Amneal Pharmaceuticals LLC	2	$49
Iovance Biotherapeutics, Inc.	2	$47

How this compares

$76,411 in reported general payments places this provider in the 70th percentile of 224 hematology & oncology providers in Indiana.

See all hematology & oncology providers in Indiana →

Medicare billing

Part B allowed, 2024

$758,899

Medicare patients

743

Services billed

34,542

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Merrillville

Bharat BaraiMerrillville$597K
Gregory DurmIndianapolis$22.7M
Nabil AdraIndianapolis$13.2M
Attaya SuvannasankhaIndianapolis$8.2M
Zhentao ZhangFort Wayne$6.4M
Shadia JalalIndianapolis$4.6M
Ahad SadiqFort Wayne$4M
Ruemu BirhirayIndianapolis$4M
Richard GaynorIndianapolis$3.7M
Ebenezer KioGoshen$2.8M

See the full list for Indiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →